DENVER, CO -- May 23, 2000 -- Allos Therapeutics, Inc.
announces positive Phase II survival results with RSR13 combined with
cranial | radiation therapy (RT) in patients with newly diagnosed
glioblastoma multiforme (GBM) brain cancer. Results were presented at
the | annual meeting of the American Society of Clinical Oncology (ASCO)
meeting in New Orleans. | | http://www.pslgroup.com/dg/1d329a.htm